PMID- 26869529
OWN - NLM
STAT- MEDLINE
DCOM- 20180126
LR  - 20180724
IS  - 1477-0970 (Electronic)
IS  - 1352-4585 (Linking)
VI  - 22
IP  - 12
DP  - 2016 Oct
TI  - Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in 
      'pattern II multiple sclerosis' and brain biopsy findings in a MOG-IgG-positive 
      case.
PG  - 1541-1549
AB  - BACKGROUND: Histopathological studies have revealed four different 
      immunopathological patterns of lesion pathology in early multiple sclerosis (MS). 
      Pattern II MS is characterised by immunoglobulin and complement deposition in 
      addition to T-cell and macrophage infiltration and is more likely to respond to 
      plasma exchange therapy, suggesting a contribution of autoantibodies. OBJECTIVE: 
      To assess the frequency of anti-myelin oligodendrocyte glycoprotein (MOG), 
      anti-M1-aquaporin-4 (AQP4), anti-M23-AQP4, anti-N-methyl-d-aspartate-type 
      glutamate receptors (NMDAR) and 25 other anti-neural antibodies in pattern II MS. 
      METHODS: Thirty-nine serum samples from patients with MS who had undergone brain 
      biopsy (n = 24; including 13 from patients with pattern II MS) and from 
      histopathologically non-classified MS patients (n = 15) were tested for anti-MOG, 
      anti-M1-AQP4, anti-M23-AQP4, anti-NMDAR, 
      anti-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor-type glutamate 
      receptors (AMPAR), anti-gamma-aminobutyric acid receptors (GABA(B)R), 
      anti-leucine-rich, glioma-activated protein 1 (LGI1), anti-contactin-associated 
      protein 2 (CASPR2), anti-dipeptidyl-peptidase-like protein-6 (DPPX), 
      anti-Tr/Delta/notch-like epidermal growth factor-related receptor (DNER), 
      anti-Hu, anti-Yo, anti-Ri, anti-Ma1/Ma2, anti-CV2/collapsin response mediator 
      protein 5 (CRMP5), anti-glutamic acid decarboxylase (GAD), anti-amphiphysin, 
      anti-Ca/RhoGTPase-activating protein 26 (ARHGAP26), 
      anti-Sj/inositol-1,4,5-trisphosphate receptor 1 (ITPR1), anti-Homer3, 
      anti-carbonic anhydrase-related protein (CARPVIII), anti-protein kinase gamma 
      (PKCgamma), anti-glutamate receptor delta 2 (GluRdelta2), anti-metabotropic 
      glutamate receptor 1 (mGluR1) and anti-mGluR5, as well as for anti-glial nuclei 
      antibodies (AGNA) and Purkinje cell antibody 2 (PCA2). RESULTS: Antibodies to MOG 
      belonging to the complement-activating immunoglobulin G1 (IgG1) subclass were 
      detected in a patient with pattern II MS. Detailed brain biopsy findings are 
      shown. CONCLUSION: This is the largest study on established anti-neural 
      antibodies performed in MS so far. MOG-IgG may play a role in a small percentage 
      of patients diagnosed with pattern II MS.
CI  - (c) The Author(s), 2016.
FAU - Jarius, Sven
AU  - Jarius S
AD  - Molecular Neuroimmunology Group, Department of Neurology, University of 
      Heidelberg, Heidelberg, Germany sven.jarius@med.uni-heidelberg.de.
FAU - Metz, Imke
AU  - Metz I
AD  - Department of Neuropathology, University Medical Center Gottingen, Gottingen, 
      Germany.
FAU - Konig, Fatima Barbara
AU  - Konig FB
AD  - Department of Neuropathology, University Medical Center Gottingen, Gottingen, 
      Germany.
FAU - Ruprecht, Klemens
AU  - Ruprecht K
AD  - Department of Neurology, Charite - Universitatsmedizin Berlin, Berlin, Germany.
FAU - Reindl, Markus
AU  - Reindl M
AD  - Clinical Department of Neurology, Medical University of Innsbruck, Innsbruck, 
      Austria.
FAU - Paul, Friedemann
AU  - Paul F
AD  - Department of Neurology, Charite - Universitatsmedizin Berlin, Berlin, Germany; 
      NeuroCure Clinical Research Center and Clinical and Experimental Multiple 
      Sclerosis Research Center, Berlin, Germany.
FAU - Bruck, Wolfgang
AU  - Bruck W
AD  - Department of Neuropathology, University Medical Center Gottingen, Gottingen, 
      Germany.
FAU - Wildemann, Brigitte
AU  - Wildemann B
AD  - Molecular Neuroimmunology Group, Department of Neurology, University of 
      Heidelberg, Heidelberg, Germany.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160211
PL  - England
TA  - Mult Scler
JT  - Multiple sclerosis (Houndmills, Basingstoke, England)
JID - 9509185
RN  - 0 (Autoantibodies)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Myelin-Oligodendrocyte Glycoprotein)
RN  - 0 (Nerve Tissue Proteins)
SB  - IM
MH  - Autoantibodies/*blood
MH  - Biopsy
MH  - Brain/immunology/*pathology
MH  - Complement Activation/*immunology
MH  - Female
MH  - Humans
MH  - Immunoglobulin G/immunology
MH  - Middle Aged
MH  - Multiple Sclerosis/*blood/*pathology
MH  - Myelin-Oligodendrocyte Glycoprotein/*immunology
MH  - Nerve Tissue Proteins/*immunology
OTO - NOTNLM
OT  - Multiple sclerosis
OT  - N-methyl-d-aspartate type glutamate receptors
OT  - aquaporin-4
OT  - autoantibodies
OT  - biopsy
OT  - complement
OT  - contactin-associated protein 2
OT  - dipeptidyl-peptidase-like protein-6
OT  - glioma-activated protein 1
OT  - histopathology
OT  - leucine-rich
OT  - metabotropic gamma-aminobutyric acid receptors
OT  - myelin oligodendrocyte glycoprotein
OT  - neuropathology
OT  - pattern II
OT  - voltage-gated potassium channels
OT  - alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor-type glutamate 
      receptors
EDAT- 2016/02/13 06:00
MHDA- 2018/01/27 06:00
CRDT- 2016/02/13 06:00
PHST- 2015/06/21 00:00 [received]
PHST- 2015/11/17 00:00 [accepted]
PHST- 2016/02/13 06:00 [pubmed]
PHST- 2018/01/27 06:00 [medline]
PHST- 2016/02/13 06:00 [entrez]
AID - 1352458515622986 [pii]
AID - 10.1177/1352458515622986 [doi]
PST - ppublish
SO  - Mult Scler. 2016 Oct;22(12):1541-1549. doi: 10.1177/1352458515622986. Epub 2016 
      Feb 11.